HCC38 Xenograft Model Service for Breast Cancer

The HCC38 xenograft model serves as a highly robust in vivo translational platform specifically designated for evaluating candidate therapies against aggressive, claudin-low triple-negative breast cancers. Alfa Cytology delivers a comprehensive, end-to-end HCC38 xenograft model service, integrating fully authenticated cellular assets with precise procedural and inoculation protocols to accelerate your preclinical oncology drug discovery timeline.

Overview of HCC38 Xenograft Model for Breast Cancer

The HCC38 cell line is a well-established human mammary carcinoma model that molecularly represents the claudin-low, basal-like subtype of triple-negative breast cancer (TNBC). Derived from a primary ductal carcinoma, this model is molecularly characterized by the complete absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification. Furthermore, HCC38 exhibits distinct mesenchymal features, including low expression of cell-cell adhesion genes and an enriched stem-cell-like signature. Due to its highly aggressive nature and clinical correlation with poor prognosis, the HCC38 model is an essential preclinical tool for investigating epithelial-to-mesenchymal transition (EMT) mechanisms, tumor angiogenesis, and for validating novel targeted small molecules or immunotherapeutic strategies.

When established in vivo as a xenograft in immunocompromised mice, HCC38 cells form solid, poorly differentiated tumors that faithfully preserve the complex histopathological microenvironment and genomic profile of clinical TNBC. This model is characterized by stable tumor engraftment and reliable growth kinetics, providing a high-sensitivity testing matrix for preclinical efficacy screenings and pharmacodynamic (PK/PD) assessments.

Cell Line Information: HCC38

The HCC38 cell line exhibits a characteristic epithelial-to-mesenchymal morphology in vitro and maintains its core phenotypic characteristics and receptor-negative status reliably upon in vivo transplantation.

Alfa Cytology is dedicated to upholding the highest benchmarks of scientific precision across all our tumor modeling operations. Our specialized oncology team utilizes fully authenticated cell lines and carefully monitored protocols to safeguard the genetic and phenotypic stability of the HCC38 model throughout the lifecycle of your study.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the HCC38 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC and PK/PD profiling. Leveraging our expertise in claudin-low triple-negative breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of HCC38 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the HCC38 xenograft model:

• Cell Culture & Quality Control: HCC38 cells are cultivated in optimized growth media. Comprehensive quality controls, including STR profiling and contamination screening, are performed to guarantee high cell viability and phenotypic identity before inoculation.
• Host Adaptation: Standardized immunocompromised mice are selected based on the study design and allowed to acclimate to our controlled facility parameters to achieve baseline physiological stability.
• Precision Inoculation: A highly viable, calibrated suspension of HCC38 cells is prepared and blended with a biological matrix carrier to optimize cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic (mammary fat pad) routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 1. HCC38 Xenograft Model Construction Workflow

Case Study - HCC38 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the HCC38 xenograft model was successfully utilized to evaluate the efficacy of a novel small-molecule inhibitor targeting the EMT pathway in triple-negative breast cancer. Our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms under optimized modeling conditions, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent tumor growth inhibition in the treatment group compared to the vehicle control.

Our Advantages

Choosing the right partner for your claudin-low triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Advanced Modeling Expertise: Broad proficiency in establishing and characterizing a diverse portfolio of human tumor models.
• Stringent Quality Control: All cell lines undergo rigorous authentication, including STR profiling, to secure baseline stability.
• Technical Reproducibility: Optimized inoculation methodologies designed to achieve uniform tumor growth kinetics.
• Comprehensive Readouts: Fully equipped to deliver multi-parametric endpoints, including high-precision tumor tracking and PK/PD tissue processing.
• Scientific Integrity: All studies are executed by a specialized team providing publication-ready data and transparent reporting.

Contact Us

Are you looking to advance your therapeutic pipeline against claudin-low, triple-negative breast cancer using the robust HCC38 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.